84,471 Guardant Health, Inc. $GH Shares Acquired by Allspring Global Investments Holdings LLC

Key Points

• Allspring increased its Guardant Health stake by 13.1%, acquiring 84,471 shares in the third quarter to hold 730,980 shares, worth about $127.7 million. Institutional investors collectively own 92.6% of the company.
• Guardant reported third-quarter revenue of about $361 million, up 36% year over year and above estimates, and a smaller-than-expected per-share loss. However, concerns about higher projected cash burn weighed on the stock despite raised revenue guidance.
• Analysts’ average rating is “Moderate Buy,” with an average price target of $191. Insiders sold 99,455 shares worth about $16.8 million over the past three months.

Allspring Global Investments Holdings LLC lifted its holdings in Guardant Health, Inc. (NASDAQ:GH - Free Report) by 13.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 730,980 shares of the company's stock after purchasing an additional 84,471 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.54% of Guardant Health worth $127,739,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GH. The Manufacturers Life Insurance Company purchased a new position in shares of Guardant Health in the second quarter worth $208,592,000. William Blair Investment Management LLC acquired a new position in shares of Guardant Health in the second quarter valued at about $196,737,000. First Light Asset Management LLC increased its holdings in shares of Guardant Health by 57.5% in the second quarter. First Light Asset Management LLC now owns 441,586 shares of the company's stock valued at $66,251,000 after purchasing an additional 161,287 shares during the period. Orbimed Advisors LLC acquired a new position in shares of Guardant Health in the first quarter valued at about $40,199,000. Finally, Sei Investments Co. raised its stake in shares of Guardant Health by 30.2% in the first quarter. Sei Investments Co. now owns 341,013 shares of the company's stock worth $31,499,000 after purchasing an additional 79,071 shares during the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Guardant Health

In other news, insider Terilyn J. Monroe sold 46,300 shares of the company's stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $165.12, for a total transaction of $7,645,056.00. Following the completion of the sale, the insider owned 22,979 shares of the company's stock, valued at $3,794,292.48. This represents a 66.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Steve E. Krognes sold 6,674 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $175.74, for a total transaction of $1,172,888.76. Following the completion of the sale, the director owned 7,906 shares of the company's stock, valued at $1,389,400.44. This trade represents a 45.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 99,455 shares of company stock valued at $16,752,081. Insiders own 5.60% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on GH shares. Stifel Nicolaus raised their price target on shares of Guardant Health from $130.00 to $180.00 and gave the stock a "buy" rating in a research report on Friday, July 31st. Mizuho upped their price objective on shares of Guardant Health from $175.00 to $200.00 and gave the company an "outperform" rating in a report on Friday, July 31st. Stephens boosted their target price on shares of Guardant Health from $170.00 to $195.00 and gave the company an "overweight" rating in a research report on Tuesday, August 4th. Rothschild & Co Redburn started coverage on shares of Guardant Health in a research report on Tuesday, September 8th. They set a "buy" rating and a $203.00 target price for the company. Finally, Sanford C. Bernstein reaffirmed an "outperform" rating and issued a $210.00 price target on shares of Guardant Health in a report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $191.00.

Guardant Health Price Performance

Shares of NASDAQ GH opened at $150.87 on Monday. The firm has a market cap of $20.25 billion, a price-to-earnings ratio of -41.00 and a beta of 1.67. The company's 50-day simple moving average is $169.31 and its 200-day simple moving average is $132.00. Guardant Health, Inc. has a 52-week low of $74.55 and a 52-week high of $191.05.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.46. The company had revenue of $360.98 million for the quarter, compared to analyst estimates of $350.72 million. The firm's revenue for the quarter was up 36.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.74) EPS. Equities research analysts anticipate that Guardant Health, Inc. will post -3.08 EPS for the current fiscal year.

Key Stories Impacting Guardant Health

Here are the key news stories impacting Guardant Health this week:

• Positive Sentiment: Third-quarter revenue increased 36% year over year to $361 million, above the cited analyst estimate of about $351 million. Oncology revenue rose 25%, while oncology test volumes climbed 58% to 117,000. Guardant also raised its 2026 revenue guidance. Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
• Positive Sentiment: The reported quarterly loss was $0.29 per share, narrower than the $0.39 loss a year earlier. Guardant Health Reports Q3 Loss, Tops Revenue Estimates
• Neutral Sentiment: A separate article suggested GH could be undervalued, while noting a board appointment as a factor investors may consider in assessing the company’s valuation. Guardant Health Could Be 17% Undervalued As Board Appointment Tests Valuation
• Negative Sentiment: The main drag was a higher cash-burn forecast, which raised concerns about spending and the path to profitability despite accelerating sales. Reports said the stock declined following the earnings announcement. Guardant Health Shares Fall as Higher Cash Burn Forecast Overshadows Strong Q3 Revenue Growth

Guardant Health Profile

Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring.

Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.